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Introduction
The complex mechanisms whereby human B cells are induced to synthesize specific antibodies have been intensely investigated over the past decade. Recently, techniques have been developed to study in vitro synthesis of Ig and specific antibody by human B lymphocytes (B cells). Activation of human peripheral bloodderived B cells with polyclonal mitogens such as pokeweed mitogen (PWM)' results in T cell-dependent synthesis and secretion of Ig by B cells (1) (2) (3) . Both T helper and T suppressor cells regulate this B cell response (1, 3) . In humans, in vivo immunization results in the appearance of several types of functional subpopulations of B cells in the peripheral blood. Lymphoblastoid B cells are detected in peripheral blood 5-8 d after booster immunizations with tetanus toxoid (TT) antigen. These cells spontaneously synthesize IgG anti-tetanus toxoid antibody (IgG-Tet) without a requirement for T helper cells or PWM (4) . Such cells are no longer detectable in the circulation by [12] [13] [14] d after immunization but are replaced by a subset of B cells that synthesize IgG-Tet in the presence of T helper cells and PWM. The latter cells persist for up to 10 wk after immunization (4, 5) .
In contrast to the IgG-Tet response, the in vitro synthesis of IgM antibody to tetanus toxoid antigen (IgM-Tet) can be induced by PWM in vitro and is not affected by in vivo booster immunization. The IgM-Tet response, like the IgG-Tet PWM response, requires T cell help (6) . However, unlike the IgG-Tet response, spontaneous synthesis of IgM-Tet by peripheral blood B cells is undetectable after booster immunization (7) .
In contrast to these considerable data regarding antibody synthesis by peripheral blood-derived B cells, there are few reports of specific antibody synthesis in vitro by bone marrow-derived B cells. We studied Ig and antibody synthesis and secretion by human bone marrow as well as peripheral blood mononuclear cells after primary and booster immunization of normal volunteers with TT antigen. After booster immunization, four functional B cell subpopulations in bone marrow were defined with respect to time of appearance and requirement for PWM. However, only one of these appeared in the bone marrow after primary immunization. Our data indicate that bone marrow B cells differ from peripheral B cells in regard to both IgG-Tet and IgM-Tet synthesis during both a primary and secondary specific antibody response.
Methods
Immunization. Five normal Oriental volunteers, 25-30 yr of age, who had never received TT immunization, served as the subjects for primary immunization. Subjects for the reimmunization (booster) studies were four normal volunteers, 30-40 yr of age, who had received routine TT immunization during childhood. Each subject received a single intramuscular booster immunization of 0.5 ml (5 flocculating units) of soluble TT (1) . PMMC B cells obtained in this fashion are devoid of T cells to the degree that alone they will not under go PWM-induced Ig synthesis.
Radioimmunoassay. Quantitative radioimmunoassays for total IgG and IgM and IgG-Tet and IgM-Tet synthesized in vitro were performed in microtiter plates (Scientific Products Inc., Baltimore, MD) as previously described (7) .
The radioimmunoassays for IgG-Tet and IgM-Tet were identical to the total IgG or IgM radioimmunoassay except that purified TT (a kind gift from Wyeth Laboratories, Marietta, PA) at a concentration of 1 mg/ml was used for the initial coating of the microtiter plates (7) .
For each radioimmunoassay a seven-point standard curve of IgG or IgM ranging from 2.5 to 50 ng was performed in parallel with the culture samples on each plate and the value for IgG or IgM extrapolated from the standard curve. Antibody to TT was also determined by comparison to the standard curve. The lower limit of detection for anti-TT antibody produced in vitro was 1 ng/culture. Standardization of specific antibody concentration may be underestimated by this procedure (6) although all batches of antisera did not show this effect when assayed against known amounts of TT antibody. This may account for some (but not all) of the discrepancy seen in specific vs. total Ig seen with spontaneous synthesis. PWM-induced synthesis of Ig or antibody to TT was determined by subtracting the quantities synthesized in cultures of cells alone from the amount produced in cultures containing PWM. The data are expressed as nanogram per 1.5 ml of culture and microgram per milliliter of serum. Individual values given in tables and figures represent the mean of duplicate cultures. The variability between cultures was generally <10%.
To check the specificity of the IgM-Tet of samples obtained from individuals before primary immunization, 25 ug of TT was added to each radioimmunoassay well in duplicate wells with the samples so as to block all specific binding. The results for these experiments are expressed as percent inhibition.
Results
Serum antibody responses. IgG-Tet was not detectable before or after a single primary TT immunization. IgM-Tet was detected (7.4 and 31.0 ,ug/ml maximum) between days 7 and 28 in two of three subjects assayed. The serum antibody response after booster immunization has been well studied with peak IgG-Tet responses (up to 250 ,ug/ml) between 10 and 21 d and no change in the low levels (-5 ,ug/ml) of IgM-Tet. (Fig. 2 A) . PWM-induced IgG-Tet synthesis increased to 116-648 ng by day 28 munization. PWM-induced total IgG synthesis ranged between 893 and 9,373 ng before immunization; there was no detectable change in total IgG synthesis over this period (Fig. 2 B) . (Fig. 3 A) ng before immunization and appeared to change in parallel tQ spontaneous synthesis of IgM-Tet (Fig. 3 B) . The percent of total IgM accounted for by IgM-Tet ranged between 2.1 and 3.4% at the peak of the spontaneous IgM-Tet response (day 7). PWM-induced synthesis of IgM-Tet and IgM. Just before booster immunization, BMMC synthesized 2.7-17.4 ng ofIgMTet in vitro in the presence of PWM (Fig. 4 A) . Although only two of the three individuals' BMMC cultures with PWM made readily detectable quantities ofIgM-Tet, all three IgM-Tet culture levels were clearly above background (Fig. 3 A) . This PWMinduced IgM-Tet synthesis increased slightly 3 or 4 wk after immunization. Total IgM synthesis by BMMC with PWM was unaffected by booster immunization (Fig. 4 B) . The percent of PWM-induced IgM accounted for by PWM-induced IgM-Tet was consistently <6% and unaffected by booster immunization. second TT injection 5 mo after his primary TT injection. However, as TT is typically given as a series of three immunizations for developing initial immunity, this second injection was not meant to be equivalent to a booster immunization. Serum IgMTet was present on the day of the second challenge (0.9 jig/ml) and showed no change over the subsequent 80 d (range 0.7-1.8 jg/ml). Serum IgG-Tet was not detectable at day 0 but became so at day 21 (10 ;ig/ml), rose to 23 gg/ml by day 36, and was still present at day 80 (6 ug/ml). B cells spontaneously secreting IgM or IgG-Tet were not detected in blood at days 7, 21, or 28 after the second immunization. In contrast, PWMinducible 13 cell production of IgG-Tet rose from very low levels at day 0 (2.8 ng) to 9.8 ng by day 21. This is still quite low compared with the levels seen after booster reimmunization. IgM-Tet that was PWM stimulated was produced at day 0 and showed no significant change after the second injection (mean 28.2 ng). These levels of PWM-induced IgM-Tet are higher than seen with this individual after the primary immunization (mean 12.7 ng) and similar to that seen in the booster-immunized subjects.
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Discussion
Despite the central role of the bone marrow in evolution of the B lymphocytes axis and development of antibody responses, there have been relatively few studies of specific antibody synthesis by human bone marrow cells (9, 10) . Reports on primary immunization have been with blood cells after in vitro immunization (1 1-14) . Data on human bone marrow synthesis of antibody after initial antigen exposure have not been reported. BMMC from patients with rheumatoid arthritis have been reported to synthesize rheumatoid factor (15) , while BMMC from patients with chronic immune thrombocytopenic purpura have been reported to synthesize autoantibodies to platelets (16). There are, however, no reports of specific antibody synthesis by human bone marrow cells in relationship to defined in vivo immunization.
We immunized four, normal, previously nonimmune and four immune volunteers with a standard immunization of TT and studied in vitro synthesis of total Ig and specific antibodies to TT by bone marrow and PBMC. After the booster immunization, we found four functional B cell subpopulations in bone marrow with respect to time ofappearance and requirement for PWM: (a) IgG-Tet "spontaneously" synthesizing cells that are present on day 7 do not require PWM and are undetectable by day 21; (b) IgG-Tet-synthesizing cells that require PWM and T cells and appear by day 21; (c) IgM-Tet-synthesizing cells that are detectable before and after booster immunization and required PWM and T cells; and (d) IgM-Tet-synthesizing cells that appear on day 7 persist for up to 21 d and are PWM independent. These subsets are probably maturational stages in the antibody response and should not be regarded as those in mutually exclusive pathways. After primary immunization, a small PWM-inducible IgG-Tet response was found in the blood at day 21, while IgM mitogen-reactive B cells could be detected in BMMC (and blood) before and after initial antigen exposure. The appearance ofthese various functional B cells is summarized in Table III. Our blocking experiments suggest the IgM-Tet detected before antigen exposure was true antibody. It might result from either the earlier expansion of low affinity TT-reactive cells by cross-reacting antigens or from the ability of PWM to induce "primary" B cells for IgM production. The latter explanation is supported by the fact that PWM has been reported to induce in vitro an IgM anti-sheep erythrocyte antibody response before antigen exposure (14) . Also although antibody to keyhole limpet hemocyanin has not been reported in culture of human lymphocytes stimulated with PWM, low levels ofanti-keyhole limpet hemocyanin antibody have been detected in serum before immunization (17) . (4) . It is likely that the influx of lymphoblastoid cells derived from lymph nodes and/or spleen into bone marrow occurs via the blood in humans and these cells are responsible for subsequent antibody synthesis detected in the bone marrow. These lymphoblastoid cells disappear from the peripheral blood by day 14 (4) and from the bone marrow by day 21 after booster immunization. Since considerable levels of IgG-Tet are detectable in the serum for years after immunization (23) this ongoing synthesis of IgGTet may occur in tissues other than the bone marrow such as lymph nodes and spleen. Alternatively, long-term anti-TT production may result from active bone marrow B cells that have such a low frequency that we have failed to detect them due to sampling error. The percentage of spontaneous specific anti-TT antibody produced by BMMC was 10% for IgG and 3% for IgM and likely reflects the fact that BMMC are actively involved in synthesis of many antibodies at any one time.
Spontaneous synthesis of IgM-Tet is not detected in human peripheral blood after booster immunization. In contrast, it is clearly present in bone marrow cells. One possible explanation for this disparity is that there are so few spontaneous IgM-Tetsynthesizing cells in peripheral blood that they cannot be detected during in vitro culture. Alternatively, IgM-Tet-synthesizing lymphoblastoid cells could arise in the bone marrow without a prior blood-borne phase as the bone marrow provides the major environment for B cell development. Studies in rodents suggest that under some circumstances it is possible to transfer immune memory from donor to recipient by the transplantation of immune spleen cells (24) . In other circumstances, immune memory is lost or impaired after adoptive transfer. In humans undergoing bone marrow transplantation it has been difficult to transfer immune memory to antigens such as purified protein derivative or Candida (25, 26) . Recipients of allogeneic HLA-A, B, C, and D-identical bone marrow transplants or transplants from genetical identical twins show profound immune deficiency for 6-12 mo after transplantation (10, (27) (28) (29) . Most data indicate that these patients respond abnormally to antigens and immunization with various antigens (29, 30) and in a fashion similar to that seen with primary TT immunization (unpublished data). One approach to this problem would be to immunize the donor to specific antigens at an appropriate time before transplantation. The data presented herein indicate that there are specific times after booster immunization when putative antibody-synthesizing cells and memory cells can be found in the bone marrow.
